Xiang Shu is the Deputy General Manager of the Marketing Center of the China National Biotec Group Company Limited (CNBG), where he oversees vaccine marketing for private markets and international trade business.
Mr Shu has more than 15 years of experience in CNBG with broad professional knowledge and practice in the biological products industry. He was involved in many research projects including “Efficacy Evaluation of Rabies Vaccine in China”, “Phase II Clinical Trial of Quadrivalent Flu Vaccine”, “Children's Birth Defect Screening Model and Comprehensive Management Strategy”, “Phase IV Clinical Trial of Combined Immunization of EV71 Vaccine”, and “Application of Pre-encapsulated Sterilized Water for Injection in Live Attenuated Varicella Vaccine.” He is familiar with research and development (R&D) and the production of biological products in China.
Mr Shu has a strong understanding of vaccine marketing in both China and overseas markets and is equipped with good perceptiveness and sharp insight in strategy development. Previously, he served as Regional Manager in the Wuhan subsidiary, Sales Director in the Lanzhou and Shanghai subsidiary, and Regional Director of east China for CNBG. He is a senior engineer of Medical Biology.